Meera Menon, MD
Internal Medicine · Phoenix, AZNPI 1427036888
Payments from drug & device makers
Across 186 payments — averaging $19.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$537
- Sanofi-aventis U.S. LLC$501
- Abbott$394
- Tandem Diabetes Care, Inc.$257
- Novo Nordisk$208
- Radius Health, Inc.$197
- plus $1K from 24 others
What the payments were for
- Speaking & faculty fees$60017%
- Food & beverage$2,91582%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 44 | $537 |
| Sanofi-aventis U.S. LLC | 9 | $501 |
| Abbott | 26 | $394 |
| Tandem Diabetes Care, Inc. | 2 | $257 |
| Novo Nordisk | 13 | $208 |
| Radius Health, Inc. | 11 | $197 |
| Amgen(2 entities) | 10 | $157 |
| Boehringer Ingelheim | 8 | $141 |
| Xeris Pharmaceuticals, Inc. | 7 | $138 |
| Insulet Corporation | 8 | $128 |
| Embecta Corp. | 5 | $115 |
| Dexcom, Inc. | 8 | $95 |
| AbbVie | 5 | $93 |
| Corcept Therapeutics | 3 | $80 |
| Cequr Corporation | 2 | $67 |
| Mannkind Corporation | 3 | $51 |
| Ascendis Pharma Endocrinology Inc | 2 | $48 |
| Verity Pharmaceuticals Inc. | 2 | $41 |
| Recordati_rare_diseases_inc. | 2 | $40 |
| Medtronic(2 entities) | 3 | $37 |
| Amneal Pharmaceuticals LLC | 2 | $33 |
| Ascensia Diabetes Care US Inc. | 2 | $31 |
| Madrigal Pharmaceuticals | 1 | $27 |
| AstraZeneca | 2 | $26 |
| Lifescan, Inc. | 1 | $18 |
| Nevro Corp. | 1 | $17 |
| Echosens North America, Inc. | 1 | $15 |
| IBSA Pharma Inc. | 1 | $15 |
| BD | 1 | $14 |
| Globus Medical | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THYROGEN$350
- t-slim insulin pump$250
How this compares
$3,535 in reported general payments places this provider in the 85th percentile of 2,212 internal medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 317 | $457,051 |
| JardianceEmpagliflozin | 236 | $286,357 |
| TrulicityDulaglutide | 133 | $193,198 |
| MounjaroTirzepatide | 90 | $127,855 |
| RybelsusSemaglutide | 22 | $52,398 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $40,955 |
| FarxigaDapagliflozin Propanediol | 42 | $38,915 |
| JanuviaSitagliptin Phosphate | 44 | $37,393 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 28 | $33,613 |
| ProliaDenosumab | 17 | $29,451 |
| Tresiba Flextouch U-200Insulin Degludec | 30 | $28,962 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $27,241 |
| Tresiba Flextouch U-100Insulin Degludec | 34 | $26,723 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 47 | $24,047 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 149 | $24,000 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $208 | $516,052353 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $537 | $327,782252 claims |
| Boehringer IngelheimJardiance | $141 | $286,357236 claims |
| AstraZenecaFarxiga | $26 | $38,91542 claims |
| AmgenProlia | $157 | $29,45117 claims |
| AbbVieSynthroid | $93 | $17,849213 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $33 | $11,0281,018 claims |
| Sanofi-aventis U.S. LLCLantus | $501 | $7,54342 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,212 internal medicine providers in Arizona.
Other internal medicine in Phoenix
- Louise TaberPhoenix$8.5M
- Ernie RifferPhoenix$3M
- Frank LovecchioPhoenix$945K
- Allison PerrinPhoenix$861K
- Nasser HajaigPhoenix$687K
- Richard TayrienPhoenix$299K
- Sanjay ShahPhoenix$288K
- Kelly KrohnPhoenix$262K
- Paul WaxPhoenix$243K
- Paul StanderPhoenix$222K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.